Jefferies Group LLC Viking Therapeutics, Inc. Call Options Transaction History

Jefferies Group LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2021 May 14, 2021	SELL	$5.74 - $9.67 $137,760 - $232,080	-24,000 Closed	0 $0
Q4 2020 Sep 21, 2023	BUY	$5.3 - $6.71 $127,200 - $161,040	24,000 New	24,000 $135,000
Q4 2020 Feb 16, 2021	BUY	$5.3 - $6.71 $127,200 - $161,040	24,000 New	24,000 $135,000
Q3 2020 Nov 13, 2020	SELL	$5.73 - $8.11 $286,500 - $405,500	-50,000 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$3.45 - $7.95 $122,130 - $281,430	-35,400 Reduced 41.45%	50,000 $234,000
Q1 2019 May 15, 2019	SELL	$7.58 - $9.94 $233,464 - $306,152	-30,800 Reduced 26.51%	85,400 $849,000
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $234,739 - $475,529	24,200 Added 26.3%	116,200 $2.02 Million
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $356,960 - $1.17 Million	92,000 New	92,000 $873,000

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.